Trading Halt
Filed with ASX · · 2 pages · English
Summary by 6ix AI
BlinkLab Limited has requested a trading halt for its securities pending an announcement regarding a national autism screening program. The halt will remain in effect until the earlier of the announcement release or the commencement of normal trading on a specified date. The company has confirmed it is not aware of any reasons why the trading halt should not be granted.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/trading-halt-615
Earlier from Blinklab
- Clinical Trial Network for Pivotal FDA Study Complete
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- High-Profile Journal Publication Validates BB1 Technology
- Appointment of Managing Director and Board Changes
Later from Blinklab
- Morocco's Nationwide Government-Funded Autism Screening
- Validation Program Commences-FDA 510(k) - First Participant
- BlinkLab Launches Pivotal US FDA Trial for AI Smartphone Autism Diagnostic
- BlinkLab Secures A$17.5M to Launch Autism Diagnostic Aid
- 2026 Annual Report & Appendix 4E
Follow Blinklab into a list and get an email when it puts out news.
Follow Blinklab